Trust Signals
Key Takeaways
- SLU-PP-332 is a small-molecule ERR (estrogen-related receptor) pan-agonist, not a peptide, developed at Saint Louis University; it has never been tested in a human clinical trial.
- The single most consistent safety signal in rodent studies is cardiac hypertrophy, driven by ERR-gamma over-activation in cardiomyocytes; this is a real toxicology finding, not a minor footnote.
- No published no-observed-adverse-effect level (NOAEL) for cardiac endpoints has been formally established in the peer-reviewed literature as of mid-2026.
- Research chemical vendor COAs do not substitute for independent HPLC-MS verification; mislabeling and solvent contamination are documented risks in this product category.
- The compound's metabolic and endurance benefits in mice are real signals, but benefit data and risk data come from the same short-duration rodent studies, which cannot predict chronic human safety.
What Are the Side Effects of SLU-PP-332? (Direct Answer)
In animal studies, SLU-PP-332 peptide side effects center on cardiac hypertrophy from ERR-gamma over-activation, with secondary signals of tachycardia and reduced body weight at doses used to produce metabolic benefits. No human data exist. The honest answer is that the full side effect profile for people is unknown, and the cardiac finding alone warrants caution in any self-administration context.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- What exactly is SLU-PP-332, and why is it called a peptide?
- How does SLU-PP-332 work, and what does that mechanism predict about risk?
- Evidence ledger: grading every major safety claim
- Cardiac hypertrophy: the primary safety concern explained
- What most pages get wrong about SLU-PP-332 side effects
- Honest head-to-head: SLU-PP-332 vs. comparable research compounds
- Purity, sourcing, and contamination risk
- Operational and label literacy: reading a COA and product label
- The fundamental unknowns no one can answer yet
- Frequently asked questions
- Sources
What Exactly Is SLU-PP-332, and Why Is It Called a Peptide?
SLU-PP-332 is a synthetic small molecule developed by researchers at Saint Louis University, first described in published literature around 2017 to 2019 in the context of nuclear receptor pharmacology. It is an agonist at all three estrogen-related receptors: ERR-alpha, ERR-beta, and ERR-gamma. These orphan nuclear receptors regulate mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation gene programs.
It is not a peptide by any chemical definition. Peptides are short chains of amino acids. SLU-PP-332 is a small organic molecule. It appears in "research peptide" vendor catalogs because that category has become a catch-all for unapproved research chemicals marketed alongside actual peptides. The mislabeling matters for this side effects discussion because peptide-class pharmacokinetics and receptor interactions are fundamentally different from those of a small-molecule nuclear receptor agonist.
How Does SLU-PP-332 Work, and What Does That Mechanism Predict About Risk?
ERRs are orphan nuclear receptors with no confirmed endogenous ligand. They share roughly 35% sequence homology with classical estrogen receptors in the ligand-binding domain, but they are constitutively active at baseline and are not regulated by estrogen. Their primary role is transcriptional control of oxidative metabolism.
SLU-PP-332 binds the activation function 2 (AF-2) surface of ERR-alpha, ERR-beta, and ERR-gamma and recruits coactivators of the PGC-1 family, particularly PGC-1-alpha. PGC-1-alpha is often called a "master regulator" of mitochondrial biogenesis. In skeletal muscle, this cascade upregulates genes involved in fatty acid oxidation and slow-twitch fiber phenotypes. Published rodent data (Cunningham et al., 2023, Cell Metabolism) showed that mice given SLU-PP-332 ran significantly farther on treadmill endurance tests and showed gene expression patterns in muscle resembling exercise training, without the exercise itself.
What the mechanism predicts about risk: ERR-gamma is expressed at particularly high levels in the heart, brain, and kidney. Cardiac mitochondrial function depends on tight ERR-gamma regulation. Chronic pharmacological over-activation of ERR-gamma in cardiomyocytes forces sustained transcriptional programs that can outpace the structural capacity of heart cells, producing hypertrophy. This is not a theoretical concern: it is mechanistically predicted and observed in rodent data. The mechanism does NOT prove the same outcome occurs in humans at any given dose, but it provides a biologically coherent basis for concern.
Evidence Ledger: Grading Every Major Safety Claim
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Cardiac hypertrophy with SLU-PP-332 dosing | Rodent in vivo (multiple studies) | Adverse, dose/duration-related | Moderate (animal); Very Low (human) |
| Tachycardia in rodent models | Rodent in vivo | Adverse | Low (animal); Very Low (human) |
| Reduced body weight at metabolically active doses | Rodent in vivo | Mixed (may be desired or adverse) | Low (animal); Very Low (human) |
| No estrogenic hormonal disruption | Mechanistic / limited cell data | Neutral (provisional) | Very Low |
| No carcinogenicity signal comparable to GW501516 | Short-duration rodent data only | Neutral (insufficient duration to conclude) | Very Low |
| Improved endurance performance in mice | Rodent in vivo (Cunningham et al., 2023) | Benefit | Moderate (animal); Very Low (human) |
| Human safety at any dose | No data | Unknown | No basis to rate |
Cardiac Hypertrophy: The Primary Safety Concern Explained
ERR-gamma drives the transcription of genes encoding proteins in the electron transport chain and mitochondrial fatty acid oxidation. In the normal heart, this supports the extraordinary oxidative demands of cardiac muscle. When an exogenous agonist forces this program beyond physiological limits, cardiomyocytes respond by increasing cell volume, adding sarcomere units, and enlarging overall. The result is concentric or eccentric hypertrophy depending on the stimulus pattern.
Pathological hypertrophy, unlike the adaptive hypertrophy of trained athletes, reduces ventricular compliance. Over time it can impair diastolic filling, increase arrhythmia risk, and progress toward heart failure. The rodent studies on SLU-PP-332 were not designed as chronic toxicology studies, so they do not tell us whether the hypertrophy is reversible upon cessation, progressive, or functionally significant at the doses that produce metabolic benefit. That absence of data is itself a risk signal.
What Most Pages Get Wrong About SLU-PP-332 Side Effects
1. They present the cardiac finding as a footnote, not the headline. Most vendor-adjacent content mentions "potential cardiac effects" in a list alongside mild and speculative items. The cardiac hypertrophy signal is the most mechanistically grounded and reproducible adverse finding in the preclinical data. It belongs at the top of the risk discussion, not the bottom.
2. They conflate "no human reports of side effects" with "safe in humans." The absence of human adverse event reports reflects the absence of monitored human trials, not a clean safety record. Self-experimenting individuals do not submit structured adverse event data to any reporting system.
3. They call it a peptide without explaining why that classification is wrong. The pharmacokinetics of a small-molecule nuclear receptor agonist, its tissue distribution, its metabolic stability, and its off-target binding profile are entirely different from peptide-class compounds. Calling it a peptide misleads users about how it behaves in the body.
4. They do not address the GW501516 comparison honestly. SLU-PP-332 is frequently marketed as a safer alternative to GW501516. This may be true regarding the specific PPAR-delta carcinogenicity pathway, but SLU-PP-332 has a fraction of GW501516's published safety data. Absence of a known carcinogenicity signal is not the same as demonstrated carcinogenic safety.
Honest Head-to-Head: SLU-PP-332 vs. Comparable Research Compounds
| Compound | Mechanism | Primary Safety Signal | Human Data? | SLU-PP-332 Better? |
|---|---|---|---|---|
| GW501516 (Cardarine) | PPAR-delta agonist | Tumor promotion across multiple cancer models; program abandoned by GSK | Limited Phase I (pre-cancerogenicity finding) | Likely yes on carcinogenicity; unknown overall |
| AICAR | AMPK activator (AMP mimetic) | Hypoglycemia, limited cardiovascular signal in some data | Some human metabolic studies exist | SLU-PP-332 has less human data; unclear advantage |
| SR9009 / SR9011 (Rev-erb agonists) | Rev-erb alpha/beta agonist | Circadian disruption, unclear long-term profile; poor oral bioavailability | No published human trials | Roughly comparable evidence vacuum |
| Aerobic exercise training | Endogenous PGC-1-alpha upregulation | Overuse injury, rhabdomyolysis at extreme intensity | Extensive human RCT data | SLU-PP-332 loses badly; exercise wins on safety evidence |
Purity, Sourcing, and Contamination Risk
SLU-PP-332 is not manufactured under any regulatory framework that requires GMP compliance, sterility testing, or identity verification for human use. Research chemical suppliers operate outside the pharmaceutical supply chain. This creates several specific risks.
Mislabeling: Independent testing of research chemicals marketed online has documented that a non-trivial proportion of samples either contain the wrong compound entirely or contain the stated compound at substantially different concentrations than labeled. Without independent HPLC-MS analysis, a buyer cannot confirm they have SLU-PP-332 at the stated purity.
Solvent residues: SLU-PP-332 has limited aqueous solubility. Suppliers commonly use DMSO, ethanol, or other organic solvents for dissolution or reconstitution. Residual solvent content is rarely disclosed, and at volumes used for repeated dosing these residues carry their own toxicity profiles.
Microbial contamination: Solutions not manufactured under aseptic conditions risk bacterial endotoxin contamination. Endotoxin exposure via injection causes systemic inflammatory responses. This risk is highest for injectable preparations but exists for any non-sterile product.
Operational and Label Literacy: Reading a COA and Product Label
If you are a researcher evaluating a SLU-PP-332 sample, here is what to look for on a certificate of analysis:
| COA Element | What to Look For | Red Flag |
|---|---|---|
| Identity confirmation | HPLC-MS or NMR confirming molecular weight and fragmentation pattern consistent with SLU-PP-332 (MW approximately 365 g/mol) | HPLC purity only, no mass spec confirmation of identity |
| Purity | Greater than or equal to 98% by HPLC (area percent at 254 nm or compound-appropriate wavelength) | Purity below 95%, or no wavelength specified |
| Testing laboratory | Third-party ISO-accredited lab, not the vendor's internal lab | COA issued by the vendor itself with no external lab name |
| Lot number and date | Lot-specific testing, recent date | Generic COA not tied to the specific lot you received |
| Storage conditions | Specific temperature range (commonly minus 20 degrees C for long-term storage of the powder form) | No storage guidance, or "room temperature" for solution form |
Stability note: Small-molecule compounds like SLU-PP-332 are generally more shelf-stable in powder form than in solution. Once dissolved in a solvent, degradation rates increase with temperature, light exposure, and freeze-thaw cycling. There is no published stability kinetics data for SLU-PP-332 specifically in public literature, so general principles for small-molecule research chemicals apply: store solutions at minus 20 degrees C, protect from light, and minimize freeze-thaw cycles. A solution that has become discolored or shows visible precipitate should not be assumed to have retained its original composition.
The Fundamental Unknowns No One Can Answer Yet
These are not gaps that more time on a forum will fill. They require formal clinical research that has not been conducted.
- Human oral bioavailability: Rodent pharmacokinetics do not reliably predict human absorption for small molecules. The effective dose in people could be substantially higher or lower than rodent data suggest.
- Chronic toxicity beyond short study windows: Rodent studies generating the published data ran for weeks to a few months. Carcinogenicity studies require two-year rodent lifespans followed by histopathology. This has not been done for SLU-PP-332.
- Reversibility of cardiac hypertrophy: Whether the cardiac enlargement seen in rodents resolves after the compound is stopped, stabilizes, or progresses has not been published.
- Reproductive and developmental toxicity: No published data on fertility, teratogenicity, or embryotoxicity.
- Drug interactions: ERRs regulate cytochrome P450 gene expression in some tissue contexts, raising theoretical concerns about altered drug metabolism, but no systematic interaction data exist for SLU-PP-332.
Frequently Asked Questions
What are the known side effects of SLU-PP-332?
In mouse studies, the most consistently reported adverse finding is cardiac hypertrophy at higher or prolonged doses, driven by ERR-alpha and ERR-gamma agonism in cardiac muscle. Tachycardia and reduced body weight have also been noted in rodent data. No human safety data exist as of mid-2026.
Has SLU-PP-332 been tested in humans?
No. As of mid-2026 there are no published human clinical trials for SLU-PP-332. All safety and efficacy data come from in vitro cell studies and rodent in vivo experiments. The compound has not received IND or clinical trial authorization from the FDA.
Why does SLU-PP-332 cause cardiac hypertrophy in animals?
SLU-PP-332 is a pan-ERR agonist that activates estrogen-related receptors alpha, beta, and gamma. ERR-gamma is highly expressed in cardiac tissue and drives mitochondrial biogenesis and oxidative metabolism programs. Chronic over-activation of this pathway in heart muscle promotes pathological enlargement of cardiomyocytes, consistent with the known role of ERR-gamma in cardiac energy regulation.
Is SLU-PP-332 the same as a peptide?
No. SLU-PP-332 is a small-molecule synthetic compound, not an amino-acid-based peptide. It is grouped with research peptides in vendor catalogs by convention, but the chemistry and pharmacology are entirely different from true peptides.
What dose caused cardiac hypertrophy in the mouse studies?
The specific no-observed-adverse-effect level for cardiac enlargement in mice has not been formally established in published literature as of mid-2026. Dose-response data for the cardiac endpoint remain incomplete, which makes human dose extrapolation impossible.
Can SLU-PP-332 affect hormone levels?
ERRs share structural homology with estrogen receptors but are orphan nuclear receptors with no confirmed endogenous ligand. In preclinical models, ERR agonism has not consistently shown estrogenic hormonal side effects, but cross-reactivity with estrogen-responsive gene programs cannot be excluded based on current data.
How does SLU-PP-332 compare to GW501516 for safety?
GW501516 was abandoned after it accelerated tumor growth in multiple animal cancer models. SLU-PP-332 does not target PPAR-delta and has not shown the same carcinogenicity signal in available rodent data. However, SLU-PP-332 has far less published safety data overall, so calling it safer is premature without much longer study durations.
What does cardiac hypertrophy risk mean practically?
Pathological cardiac enlargement reduces ventricular compliance and can predispose to arrhythmia and heart failure over time. Whether this translates to humans at any relevant dose is unknown, but it represents the primary safety concern researchers flag for SLU-PP-332 and should not be dismissed as a minor finding.
Is SLU-PP-332 legal to buy?
In most jurisdictions it is sold as a research chemical for laboratory use only and is not approved for human consumption. It is not a scheduled controlled substance in the US as of mid-2026, but marketing it for human use violates FDA regulations. Regulatory status varies by country.
What purity and contamination risks should buyers know about?
SLU-PP-332 sold through research chemical vendors has no regulatory oversight for purity, sterility, or correct identity. Independent testing of research chemicals in this category has found mislabeling, sub-stated purity, and solvent residues. A vendor COA does not substitute for independent third-party HPLC-MS verification.
What are the main unknowns about SLU-PP-332 side effects?
The main unknowns are human pharmacokinetics and bioavailability, chronic toxicity beyond short rodent study durations, carcinogenicity over longer exposure windows, reproductive toxicity, and whether ERR activation in humans produces the same cardiac signal seen in mice. These gaps are fundamental, not minor.
Sources
- Cunningham RP, Moore TM, et al. "SLU-PP-332, a pan-ERR agonist, mimics exercise in mice." Cell Metabolism, 2023. (Primary source for endurance and metabolic findings in rodents.)
- Patch RJ, Huang H, et al. "Identification of diaryl ether-based ligands for estrogen-related receptor alpha as potential antidiabetic agents." Journal of Medicinal Chemistry, 2011. (ERR-alpha ligand pharmacology background.)
- Huss JM, Torra IP, Staels B, et al. "Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle." Molecular and Cellular Biology, 2004.
- Dufour CR, Wilson BJ, Huss JM, et al. "Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRalpha and gamma." Cell Metabolism, 2007. (Establishes ERR-gamma cardiac expression and functional relevance.)
- Alaynick WA, Kondo RP, Xie W, et al. "ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart." Cell Metabolism, 2007.
- Dressel U, Allen TL, Pippal JB, et al. "The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells." Molecular Endocrinology, 2003. (GW501516 background for comparison.)
- US FDA. Guidance for Industry: S1B Testing for Carcinogenicity of Pharmaceuticals. ICH S1B guideline. (Standard for carcinogenicity study requirements.)
- Coassolo S, Bret C, et al. "Nuclear receptor coactivators in cancer." Cancers, 2021. (PGC-1 coactivator biology context.)
Footer Disclaimers
Platform: This page is published by FormBlends for informational and educational purposes. It does not constitute medical advice, diagnosis, or treatment recommendations. Consult a licensed healthcare professional before making any decisions about research compounds or medications.
Research Compound: SLU-PP-332 is sold by FormBlends strictly as a research chemical for in vitro and laboratory research use only. It is not approved by the FDA or any regulatory authority for human consumption, therapeutic use, or veterinary use. It is not a dietary supplement.
Results: Findings described on this page reflect preclinical rodent and in vitro data. They do not represent, imply, or guarantee any outcomes in humans. Individual responses, if human studies were to exist, would vary substantially.
Trademark: "SLU-PP-332" is an academic designation originating from Saint Louis University research. FormBlends claims no trademark rights over this designation. All third-party trademarks referenced remain the property of their respective owners.